MX2016015484A - Inhibidores del factor xia. - Google Patents

Inhibidores del factor xia.

Info

Publication number
MX2016015484A
MX2016015484A MX2016015484A MX2016015484A MX2016015484A MX 2016015484 A MX2016015484 A MX 2016015484A MX 2016015484 A MX2016015484 A MX 2016015484A MX 2016015484 A MX2016015484 A MX 2016015484A MX 2016015484 A MX2016015484 A MX 2016015484A
Authority
MX
Mexico
Prior art keywords
factor xia
compounds
xia inhibitors
inhibitors
formula
Prior art date
Application number
MX2016015484A
Other languages
English (en)
Spanish (es)
Inventor
Zhuyan Guo
Scott D Edmondson
Rongze Kuang
Amjad Ali
Linda L Brockunier
So Sung-Sau
Heping Wu
Wanying Sun
Mertz Eric
Liu Weiguo
K Ogawa Anthony
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2016015484A publication Critical patent/MX2016015484A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2016015484A 2014-05-28 2015-05-22 Inhibidores del factor xia. MX2016015484A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462003693P 2014-05-28 2014-05-28
PCT/US2015/032091 WO2015183709A1 (en) 2014-05-28 2015-05-22 Factor xia inhibitors

Publications (1)

Publication Number Publication Date
MX2016015484A true MX2016015484A (es) 2017-03-23

Family

ID=54699606

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015484A MX2016015484A (es) 2014-05-28 2015-05-22 Inhibidores del factor xia.

Country Status (10)

Country Link
US (1) US9783530B2 (OSRAM)
EP (1) EP3148542B1 (OSRAM)
JP (1) JP2017517512A (OSRAM)
KR (1) KR20170005871A (OSRAM)
CN (1) CN106413710A (OSRAM)
AU (1) AU2015267305A1 (OSRAM)
CA (1) CA2947987A1 (OSRAM)
MX (1) MX2016015484A (OSRAM)
RU (1) RU2016150410A (OSRAM)
WO (1) WO2015183709A1 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6479763B2 (ja) 2013-03-25 2019-03-06 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 第xia因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン
NO2760821T3 (OSRAM) 2014-01-31 2018-03-10
UY35971A (es) 2014-01-31 2015-07-31 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Macrociclos con grupos p2? aromáticos como inhibidores del factor xia
US9975874B2 (en) 2014-07-28 2018-05-22 Merck Sharp & Dohme Corp. Factor XIa inhibitors
CN107074821B (zh) 2014-09-04 2020-05-22 百时美施贵宝公司 为fxia抑制剂的二酰胺大环化合物
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
BR112017015431A2 (pt) * 2015-01-20 2018-01-16 Merck Sharp & Dohme composto, composição farmacêutica, métodos para inibir a formação de trombos no sangue ou tratar uma formação de trombos no sangue, para impedir a formação de trombos no sangue, para tratar tromboembolismo venoso e embolia pulmonar, para tratar trombose venosa profunda e para tratar ataque tromboembólico, e, uso de um composto
US10472344B2 (en) * 2015-12-02 2019-11-12 Merck Sharp & Dohme Corp. Factor XIa inhibitors
TW201808908A (zh) 2016-08-22 2018-03-16 美商默沙東藥廠 因子XIa抑制劑
CN111763171B (zh) * 2019-04-02 2023-12-22 上海美悦生物科技发展有限公司 一种FXIa凝血因子抑制剂及其药物组合物、制备方法和医药用途
EP4036087A4 (en) * 2019-09-27 2023-09-20 Shenzhen Salubris Pharmaceuticals Co. Ltd Fxia inhibitors and preparation method therefor and pharmaceutical use thereof
CN116348109B (zh) * 2020-09-17 2025-01-21 浙江海正药业股份有限公司 哌嗪类衍生物及其制备方法和用途
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429604B2 (en) * 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
MX2007013198A (es) * 2005-04-20 2008-03-24 Johnson & Johnson Moduladores de trombina de n-oxido de piridina fluorado y procedimiento para n-oxidacion de heteroarilos que contienen nitrogeno.
WO2007070818A1 (en) * 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US7829584B2 (en) * 2006-03-21 2010-11-09 Janssen Pharmaceutica Nv Pyridines and pyridine N-oxides as modulators of thrombin
CN101784516B (zh) * 2007-06-13 2014-07-02 百时美施贵宝公司 作为凝血因子抑制剂的二肽类似物
WO2013009527A2 (en) * 2011-07-08 2013-01-17 Merck Sharp & Dohme Corp. Factor ixa inhibitors
US9975874B2 (en) 2014-07-28 2018-05-22 Merck Sharp & Dohme Corp. Factor XIa inhibitors
US10011585B2 (en) 2014-07-28 2018-07-03 Merck Sharp & Dohme Corp. Factor XIa inhibitors
EP3180317B1 (en) 2014-07-28 2021-04-14 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS

Also Published As

Publication number Publication date
AU2015267305A1 (en) 2016-11-03
EP3148542A4 (en) 2018-01-03
CA2947987A1 (en) 2015-12-03
RU2016150410A3 (OSRAM) 2018-11-30
WO2015183709A1 (en) 2015-12-03
RU2016150410A (ru) 2018-06-28
US9783530B2 (en) 2017-10-10
CN106413710A (zh) 2017-02-15
JP2017517512A (ja) 2017-06-29
KR20170005871A (ko) 2017-01-16
EP3148542B1 (en) 2019-02-27
US20170197953A1 (en) 2017-07-13
EP3148542A1 (en) 2017-04-05

Similar Documents

Publication Publication Date Title
MX2016015484A (es) Inhibidores del factor xia.
MX387515B (es) Inhibidores de factor xia.
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
PH12018500457A1 (en) New phenoxymethyl derivatives
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
PH12016500330B1 (en) Certain chemical entities, compositions, and methods
TN2018000229A1 (en) Pyrimidinones as factor xia inhibitors
PH12018500409A1 (en) New bicyclic compounds as dual atx/ca inhibitors
MX2016011556A (es) Composiciones que comprenden un agente amargante.
SG11201703988PA (en) N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors,
EA201791133A1 (ru) Ингибиторы erk
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
PH12017501523A1 (en) Selective bace1 inhibitors
MX2016011558A (es) Composiciones que comprenden un agente amargante.
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2017009445A (es) Inhibidores del factor xia.
MX2016011553A (es) Composiciones que comprenden un agente pungente.
MA40457A (fr) Combinaison de médicaments pour traiter le myélome multiple
PH12017501879A1 (en) Methods for treating cancer
TW201613892A (en) Forms and compositions of an ERK inhibitor
NZ729087A (en) Azetidinyloxyphenylpyrrolidine compounds
PH12017501880A1 (en) Methods for treating cancer
MX2016015298A (es) Inhibidores de nampt y metodos.